Strides Arcolab’s subsidiary receives US FDA approval for Cytarabine

15 Dec 2011 Evaluate

Strides Arcolab’s wholly owned subsidiary Onco Therapies, has received US FDA approval for Cytarabine Injection 20mg/ml, packaged in 500mg/ 25ml multiple-dose vials, 20mg/ml, packaged in 100mg/ 5ml single dose vial and 20mg/ml, packaged in 1000mg/50ml Pharmacy bulk package.

Cytarabine is an anti-cancer chemotherapy drug. It is used to treat different forms of leukemia, including acute and chronic myelogenous and acute lymphocytic leukemia. It is also used to treat lymphoma, meningeal leukemia and lymphoma (cancers found in the lining of the brain and spinal cord).

The US market for Cytarabine Injection is about $12.30 million. Cytarabine is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.

Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufacturers a wide range of IP-led niche pharmaceuticals products with an emphasis on sterlite injectables.

Strides Pharma Scien Share Price

938.40 -31.50 (-3.25%)
24-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1737.50
Dr. Reddys Lab 1266.35
Cipla 1496.35
Zydus Lifesciences 917.45
Lupin 2109.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×